Latest news with #UmbilicalCordStemCell
Yahoo
16-05-2025
- Business
- Yahoo
Adia Nutrition Inc. Files for OTCQB Uplisting with OTC Markets, Emphasizing OTC-Handled 15c2-11 for Transparency and Investor Reach
Winter Park, Florida--(Newsfile Corp. - May 16, 2025) - Adia Nutrition Inc. (OTC Pink: ADIA), a leader in regenerative medicine and nutritional wellness, proudly announces that it has officially filed with OTC Markets Group for uplisting to the OTCQB Venture Market. This filing follows the successful completion of an independent audit with Astra Audit and Advisory LLC on April 1, 2025, marking a significant milestone in the company's commitment to enhancing visibility, liquidity, and shareholder value through its innovative stem cell therapies and premium nutritional products. As part of this uplisting process, OTC Markets will handle Adia Nutrition's Form 15c2-11, a critical step under SEC regulations that enables broker-dealers to quote the company's securities. By having OTC Markets facilitate this streamlined review, Adia benefits from a more efficient path to public quotation compared to traditional FINRA filings. This process ensures current financial and operational information is publicly available, boosting transparency and investor confidence. The 15c2-11 completion will also enhance market maker participation, improving trading efficiency, liquidity, and price discovery—key advantages as Adia transitions to the OTCQB's higher reporting standards and broader investor reach. OTCQB Up ListingTo view an enhanced version of this graphic, please visit: Additionally, Adia Nutrition has requested the Non-Objecting Beneficial Owners (NOBO) list, a strategic move to strengthen shareholder engagement. Obtaining the NOBO list allows the company to directly communicate with street-name shareholders who do not object to sharing their contact details, bypassing intermediaries like brokers. This direct access enhances Adia's ability to share updates on its pioneering work—such as Umbilical Cord Stem Cell (UCB-SC) therapies and Autologous Hematopoietic Stem Cell Transplantation (aHSCT)—while building closer ties with investors and potentially increasing participation in corporate actions like voting or investment opportunities. "We're thrilled to take this next step toward the OTCQB," said Larry Powalisz, CEO of Adia Nutrition Inc. "Filing for uplisting, leveraging OTC Markets for our 15c2-11, and requesting the NOBO list reflect our focus on transparency and growth. These moves not only elevate our market presence but also connect us more directly with the investors who believe in our mission to transform healthcare through stem cell innovation and nutritional excellence." With this filing, Adia Nutrition is poised to capitalize on the OTCQB's benefits, including greater market credibility and access to a wider investor base, as it continues to expand its network of clinics and advance its science-backed solutions. The company remains on track with its broader roadmap toward a potential Nasdaq Small Cap listing, reinforcing its position as a pioneer in regenerative medicine. For questions, inquiries or further information, please contact Larry Powalisz at ceo@ or 321-788-0850. About ADIA Nutrition Inc.:Adia Nutrition Inc. is a publicly traded company (OTC Pink: ADIA) dedicated to revolutionizing healthcare and supplementation. With a focus on innovation and quality, the company has established two key divisions: a supplement division providing premium, organic supplements, and a medical division establishing Clinics that specialize in leading-edge stem cell therapies, most significantly Umbilical Cord Stem Cells (UCB-SC) and Autologous Hematopoietic Stem Cell Transplantation (aHSCT) treatments. Through these divisions, Adia Nutrition Inc. is committed to empowering individuals to live their best lives by addressing both nutritional needs and groundbreaking medical treatments. Website: Website: (X): @ADIA_Nutrition Safe Harbor: This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a few uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The company undertakes no obligation to publicly update or revise any forward-looking statements, because of new information, future events or otherwise. To view the source version of this press release, please visit
Yahoo
14-04-2025
- Business
- Yahoo
Adia Nutrition Inc. Files for OTCQB Uplisting with OTC Markets, Emphasizing OTC-Handled 15c2-11 for Transparency and Investor Reach
Winter Park, Florida--(Newsfile Corp. - April 14, 2025) - Adia Nutrition Inc. (OTC Pink: ADIA), a leader in regenerative medicine and nutritional wellness, proudly announces that it has officially filed with OTC Markets Group for uplisting to the OTCQB Venture Market. This filing follows the successful completion of an independent audit with Astra Audit and Advisory LLC on April 1, 2025, marking a significant milestone in the company's commitment to enhancing visibility, liquidity, and shareholder value through its innovative stem cell therapies and premium nutritional products. As part of this uplisting process, OTC Markets will handle Adia Nutrition's Form 15c2-11, a critical step under SEC regulations that enables broker-dealers to quote the company's securities. By having OTC Markets facilitate this streamlined review, Adia benefits from a more efficient path to public quotation compared to traditional FINRA filings. This process ensures current financial and operational information is publicly available, boosting transparency and investor confidence. The 15c2-11 completion will also enhance market maker participation, improving trading efficiency, liquidity, and price discovery-key advantages as Adia transitions to the OTCQB's higher reporting standards and broader investor reach. Additionally, Adia Nutrition has requested the Non-Objecting Beneficial Owners (NOBO) list, a strategic move to strengthen shareholder engagement. Obtaining the NOBO list allows the company to directly communicate with street-name shareholders who do not object to sharing their contact details, bypassing intermediaries like brokers. This direct access enhances Adia's ability to share updates on its pioneering work-such as Umbilical Cord Stem Cell (UCB-SC) therapies and Autologous Hematopoietic Stem Cell Transplantation (aHSCT)-while building closer ties with investors and potentially increasing participation in corporate actions like voting or investment opportunities. "We're thrilled to take this next step toward the OTCQB," said Larry Powalisz, CEO of Adia Nutrition Inc. "Filing for uplisting, leveraging OTC Markets for our 15c2-11, and requesting the NOBO list reflect our focus on transparency and growth. These moves not only elevate our market presence but also connect us more directly with the investors who believe in our mission to transform healthcare through stem cell innovation and nutritional excellence." With this filing, Adia Nutrition is poised to capitalize on the OTCQB's benefits, including greater market credibility and access to a wider investor base, as it continues to expand its network of clinics and advance its science-backed solutions. The company remains on track with its broader roadmap toward a potential Nasdaq Small Cap listing, reinforcing its position as a pioneer in regenerative medicine. For questions, inquiries or further information, please contact Larry Powalisz at ceo@ or 321-788-0850. About ADIA Nutrition Inc.:Adia Nutrition Inc. is a publicly traded company (OTC Pink: ADIA) dedicated to revolutionizing healthcare and supplementation. With a focus on innovation and quality, the company has established two key divisions: a supplement division providing premium, organic supplements, and a medical division establishing Clinics that specialize in leading-edge stem cell therapies, most significantly Umbilical Cord Stem Cells (UCB-SC) and Autologous Hematopoietic Stem Cell Transplantation (aHSCT) treatments. Through these divisions, Adia Nutrition Inc. is committed to empowering individuals to live their best lives by addressing both nutritional needs and groundbreaking medical treatments. Website: Website: (X): @ADIA_Nutrition Safe Harbor: This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a few uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The company undertakes no obligation to publicly update or revise any forward-looking statements, because of new information, future events or otherwise. To view the source version of this press release, please visit
Yahoo
24-02-2025
- Business
- Yahoo
ADIA Nutrition Inc. Embarks on Nationwide Expansion of Adia Med Satellite Locations
Winter Park, Florida--(Newsfile Corp. - February 24, 2025) - ADIA Nutrition Inc. (OTC Pink: ADIA), a leader in healthcare innovation and regenerative medicine, proudly announces its strategic expansion plan for Adia Med satellite locations across the United States. This initiative aims to make Adia Med's innovative treatments more accessible by partnering with premier Medical Spas dedicated to anti-aging, wellness, and body repair. ADIA Nutrition Inc. Embarks on Nationwide Expansion of Adia Med Satellite LocationsTo view an enhanced version of this graphic, please visit: ADIA Nutrition will collaborate with elite Med Spas, leveraging their established infrastructure, reputation, and customer base to introduce Adia Med's advanced treatments. This partnership model creates a beneficial synergy for both partners, enhancing the service offerings of the Med Spas while broadening Adia Med's reach. The expansion will initially target regions where there's a high demand for longevity, anti-aging, and regenerative treatments, focusing on major cities and affluent suburbs known for their health-conscious demographics. Satellite locations will offer a curated selection of Adia Med's services, including Umbilical Cord Stem Cell (UCB-SC) therapies, stem cell injectables, and other regenerative solutions, which will complement and enhance the existing Med Spa services, providing a comprehensive approach to health and beauty. To maintain the high standard of care, ADIA Nutrition will provide comprehensive training for Adia's medical professionals alongside rigorous quality control measures. This ensures that the integrity and effectiveness of Adia Med treatments remain consistent across all locations. The expansion will proceed in phases, starting with pilot programs to refine the operational model before a broader rollout, ensuring each step leverages the success of the previous. Investment and Growth Potential By partnering with Med Spas, Adia Med can significantly expand its market presence with reduced overhead costs, offering Adia a model with lower risk and high scalability. This approach introduces multiple revenue streams through service fees, royalties, and potential equity interests, creating a robust financial framework. The synergy between Adia Med and its Med Spa partners not only increases market penetration but also enhances revenue potential by tapping into an already engaged clientele interested in wellness and anti-aging solutions. Larry Powalisz, CEO of ADIA Nutrition, stated, "Here is a piece of the roadmap of our expansion as promised. This expansion into satellite locations through strategic partnerships with premier Med Spas is a testament to our commitment to making our life-changing therapies more accessible. We believe this model not only accelerates our growth but also aligns perfectly with our vision for regenerative medicine." This strategic expansion lays the groundwork for future product and service introductions, utilizing the existing network for rapid market adoption and providing valuable feedback for continuous innovation. ADIA Nutrition invites current and potential shareholders to follow this exciting development, promising to redefine healthcare accessibility and efficacy. Larry Powalisz also highlighted that the success of this initiative stems from the mutual benefits it offers; every successful Med Spa will significantly benefit from Adia Med's ability to help existing patients and attract new ones, bolstered by a generous commission structure that ensures financial benefits for all parties involved. For inquiries or further information, Med Spas and medical professionals are encouraged to contact Larry Powalisz at ceo@ or 321-788-0850. About ADIA Nutrition Inc.:Adia Nutrition Inc. is a publicly traded company (OTC Pink: ADIA) dedicated to revolutionizing healthcare and supplementation. With a focus on innovation and quality, the company has established two key divisions: a supplement division providing premium, organic supplements, and a medical division establishing Clinics that specialize in leading-edge stem cell therapies, most significantly Umbilical Cord Stem Cells (UCB-SC) and Autologous Hematopoietic Stem Cell Transplantation (aHSCT) treatments. Through these divisions, Adia Nutrition Inc. is committed to empowering individuals to live their best lives by addressing both nutritional needs and groundbreaking medical treatments. Website: Website: Website: Website: Twitter (X): @ADIA_Nutrition Safe Harbor: This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a few uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The company undertakes no obligation to publicly update or revise any forward-looking statements, because of new information, future events or otherwise. To view the source version of this press release, please visit
Yahoo
18-02-2025
- Business
- Yahoo
Adia Med Partners with Premier FDA-Approved Lab for High-Quality Umbilical Cord Stem Cell and Exosome Products
Winter Park, Florida--(Newsfile Corp. - February 18, 2025) - Adia (OTC Pink: ADIA) Med is proud to announce a strategic partnership with an FDA-approved laboratory in the field of regenerative medicine. This collaboration marks a new era in the availability of top-tier, third-party verified, and minimally manipulated umbilical cord stem cell and exosome products. Adia Med Partners with Premier FDA-Approved Lab for High-Quality Umbilical Cord Stem Cell and Exosome Products To view an enhanced version of this graphic, please visit: Following exhaustive research, Adia Med has selected this lab for its unparalleled expertise and compliance with the highest regulatory standards. The lab's commitment to quality, safety, and innovation has been crucial in ensuring that Adia Med can offer products that meet the stringent demands of medical professionals and patients alike. CEO of Adia Nutrition, Larry Powalisz stated, "After months of due diligence and building strategic relationships within our medical niche, I can with unreserved confidence say that not only do we offer the best quality therapies but also the best quantities per treatment." Key Attributes of Our Lab Partner: FDA Approval: The laboratory has achieved FDA approval, underscoring its adherence to rigorous safety and quality protocols for biologics. Quality Assurance: All products undergo third-party verification, ensuring that each batch of stem cells and exosomes is of the highest purity, potency, and viability. Minimal Manipulation: The lab's techniques are designed to preserve the natural state and therapeutic properties of the cells, offering minimally manipulated products that are both effective and safe. Research Excellence: Known for its groundbreaking research, the lab has been instrumental in pinpointing the best sources for umbilical cord stem cells, which are celebrated for their high regenerative potential and low risk of rejection. Broad Therapeutic Applications: The partnership will enable the distribution of these advanced products, which hold promise for applications in orthopedics, neurology, dermatology, and more. Dr. Monica Sher, director of Umbilical Cord Stem Cell (UCB-SC) Treatments at Adia Med, expressed enthusiasm about the partnership, stating, "Our collaboration with this exceptional lab is a testament to our dedication to excellence in regenerative medicine. Their reputation for quality and compliance with FDA standards ensures that we can offer the best possible products to the medical community." Following rigorous research into the sourcing and optimization of umbilical cord stem cells, Adia Med has identified what they believe to be the most potent and pure stem cells available. The lab has formulated a product with an unprecedented concentration of 100 million umbilical cord stem cells and 3 trillion exosomes per dose, designed to maximize therapeutic impact for a wide range of conditions. Key Applications: Clinical Trials: Researchers will have access to a consistent, high-quality source of stem cells and exosomes for studying regeneration and repair mechanisms. Therapeutic Use: The product is poised for use in treatments aimed at conditions ranging from orthopedic injuries to neurodegenerative diseases, where stem cell therapy can offer non-invasive, regenerative solutions. Preventive Medicine: Potential applications in anti-aging and wellness, leveraging the regenerative properties of stem cells and exosomes. Adia Med is committed to ensuring this premium product reaches healthcare providers who are at the forefront of regenerative medicine. Clinicians interested in this new offering can find more information or engage in partnerships by visiting Adia Med's official website ( or contacting their support team. For media inquiries or further information, please contact Larry Powalisz at ceo@ or 321-788-0850. About ADIA Nutrition Inc.:Adia Nutrition Inc. is a publicly traded company (OTC Pink: ADIA) dedicated to revolutionizing healthcare and supplementation. With a focus on innovation and quality, the company has established two key divisions: a supplement division providing premium, organic supplements, and a medical division establishing Clinics that specialize in leading-edge stem cell therapies, most significantly Umbilical Cord Stem Cells (UCB-SC) and Autologous Hematopoietic Stem Cell Transplantation (aHSCT) treatments. Through these divisions, Adia Nutrition Inc. is committed to empowering individuals to live their best lives by addressing both nutritional needs and groundbreaking medical treatments. Website: Website: Website: Website: Twitter (X): @ADIA_Nutrition Safe Harbor: This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a few uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The company undertakes no obligation to publicly update or revise any forward-looking statements, because of new information, future events or otherwise. To view the source version of this press release, please visit Sign in to access your portfolio
